7/7/2019 Abeona Director Implicated In 'Pump And Dump' Lawsuit With SEC Investigation, Price Target Of Zero - Abeona Therapeutics Inc. (NASDAQ:ABEO) …


https://seekingalpha.com/article/4035215-abeona-director-implicated-pump-dump-lawsuit-sec-investigation-price-target-zero 1/12


Short Ideas  |  Healthcare 


Abeona Director Implicated In 'Pump And Dump' Lawsuit With SEC
Investigation, Price Target Of Zero
Jan. 9, 2017 9:30 AM ET95 comments
by: Mako Research


Summary


ABEO Director Mark Ahn appears to have settled an SEC investigation for his
involvement in an illegal stock promotion when he served as the CEO of Galena
Pharmaceuticals (GALE).


Before being sued, Ahn allegedly promoted GALE with illegal stock promotion
campaigns costing hundreds of thousands of dollars, then dumped millions of dollars
of his stock, enriching himself.


This is not surprising to us as ABEO’s board is filled with stock promoters, including
Chairman Steven Rouhandeh, who has a long and similar history of promotion and
self­enrichment.


Two sell­side "analysts" defending ABEO were involved in numerous China fraud
wipeouts while at Rodman & Renshaw. ABEO shares are worth nothing. We
downgrade ABEO.


We believe shares of Abeona (NASDAQ:ABEO) are objectively without value and
apparently exist to enrich insiders at the expense of investors. This report is the second
installment in our ongoing coverage of the ABEO stock promotion, and will focus
exclusively on those responsible for perpetrating this stock promotion. Future reports will
further elaborate on why ABEO's science is unviable and set to fail.


When investing in speculative, cash burning, biotech stocks with unproven science and
many years of failure, everyone would agree it is critical to understand the quality of the
people in charge. Even a valuable product or business, if run by questionable people, will
likely end up wiping out shareholders. Stock market history is littered with the corpses of
businesses which had a chance but failed and disappeared permanently due to poor
management. We believe ABEO's science is obviously unviable but even if you disagree
on that point, it is vital that you understand the people in charge of this company who you
have entrusted your savings with as an investor.



https://seekingalpha.com/stock-ideas/short-ideas

https://seekingalpha.com/stock-ideas/healthcare

https://seekingalpha.com/symbol/ABEO
7/7/2019 Abeona Director Implicated In 'Pump And Dump' Lawsuit With SEC Investigation, Price Target Of Zero - Abeona Therapeutics Inc. (NASDAQ:ABEO) …


https://seekingalpha.com/article/4035215-abeona-director-implicated-pump-dump-lawsuit-sec-investigation-price-target-zero 2/12


ABEO Director Mark Ahn: Subject of SEC Investigation Regarding Illegal "Pump &
Dump" Stock Promotion


We believe that ABEO shareholders are completely unaware of an 8­K filing that was
snuck out during the holiday season, which appears to disclose that current ABEO
Director Mark Ahn and the company he was previously the president and CEO of, Galena
Biopharma (GALE), have agreed on a proposed settlement regarding the SEC's long­
running investigation of his alleged commissioning of an illegal stock promotion where he
dumped many millions of dollars of personal stock in alleged violation of securities laws.


Specifically, we quote the 8­K:


"On December 22, 2016, Galena Biopharma, Inc. (Galena) and its former Chief
Executive Officer (CEO) reached an agreement in principle to a proposed settlement
that would resolve an investigation by the staff of the Securities and Exchange
Commission (SEC) involving conduct in the period 2012­2014 regarding the
commissioning of internet publications by outside promotional firms."


GALE mysteriously did not include Mark Ahn's name in the 8­K so it is not stated clearly
but we don't see how the "former Chief Executive Officer" during 2012­2014 it is referring
to in the 8­K is possibly anyone other than ABEO's current Director, Mark Ahn since Mark
Ahn was the previous CEO of GALE during the time period.


What's even more alarming to us is that none of these events, including Mark Ahn's
questionable background, have been disclosed to ABEO shareholders that we're aware
of, not to mention that Ahn remains on the board of ABEO to this day despite the legal
swamp he has found himself in. We strongly believe all legal matters, federal
investigations, and/or securities fraud lawsuits involving ABEO directors should be made
immediately known to ABEO investors. In the spirit of full disclosure and transparency,
we'll once again lend a hand to ABEO shareholders based on this publicly available
information so they are hopefully able to make more informed investment decisions in the
future about who they have entrusted their wealth to.


Let's review the timeline of events, which in our view, ultimately resulted in GALE
shareholders losing substantial amounts of value since Mark Ahn joined the company.
Recall that many of Rouhandeh's prior stock promotions ended similarly at essentially
zero, and in our opinion, there is a very clear pattern here. Readers needing a full



https://www.bamsec.com/filing/139047816000167?cik=1390478

https://seekingalpha.com/news/3232330-galena-reaches-settlement-former-ceo-sec-inquiry-dubious-stock-promotion-scheme-shares-ahead
7/7/2019 Abeona Director Implicated In 'Pump And Dump' Lawsuit With SEC Investigation, Price Target Of Zero - Abeona Therapeutics Inc. (NASDAQ:ABEO) …


https://seekingalpha.com/article/4035215-abeona-director-implicated-pump-dump-lawsuit-sec-investigation-price-target-zero 3/12


refresher on the substantial shareholder value destruction that Rouhandeh has wrought
on the capital markets over time should read our initial report debunking ABEO, which can
be found here.


Mark Ahn joined GALE in 2007 serving as a director of the company, and in 2011, Mark
Ahn entered into a new role to serve as GALE's president and chief executive officer.
Shortly after taking these leadership positions, numerous Seeking Alpha articles were
published blatantly promoting GALE. These articles seemed to create quite the internet
buzz as shown by Google Trends:


Source: Google Trends


There's no doubt this was a serious stock promotion based on the public lawsuits. Court
documents showed that the stock promoters that Mark Ahn allegedly commissioned
published a total of 50 unique "GALE­centered blogs" that were distributed through
various investment sites. The stock promoters that Mark Ahn allegedly commissioned also
apparently paid other people to tout GALE on message boards as well as Facebook
(NASDAQ:FB) and Twitter (NYSE:TWTR) as outlined in the 2015 complaint for violations
of securities laws against Galena Biopharma, Mark J. Ahn and others.


We strongly encourage ABEO shareholders to review the following chart closely as it
details how over $750 million of value was destroyed by Ahn and promoters involved at
GALE since the height of the promotion. The key takeaway here is that ever since Mark
Ahn involved himself with GALE, it has lost substantially all of its value:



https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent

https://www.bamsec.com/filing/95013508002535/1?entity_id=1390478&hl=360577:360641&hl_id=ej405iism

https://www.bamsec.com/filing/95012311033025/1?entity_id=1390478&hl=11184:11394&hl_id=41qg1fhem

https://www.google.com/trends/explore?date=all&q=/m/0j3gp7q

https://seekingalpha.com/symbol/FB

https://seekingalpha.com/symbol/TWTR

https://static.seekingalpha.com/uploads/2017/1/40228756_14839399560396_rId15.png
7/7/2019 Abeona Director Implicated In 'Pump And Dump' Lawsuit With SEC Investigation, Price Target Of Zero - Abeona Therapeutics Inc. (NASDAQ:ABEO) …


https://seekingalpha.com/article/4035215-abeona-director-implicated-pump-dump-lawsuit-sec-investigation-price-target-zero 4/12


Eventually, after he blew out of $3.8 million worth of stock during the alleged stock
promotion, Mark Ahn became a named defendant in at least two securities fraud lawsuits:


Source Link


(1) https://www.bamsec.com/filing/95012311033025/1?


entity_id=1390478&hl=11183:11394&hl_id=vka6_4srg


(2) http://www.law360.com/articles/734388/galena­to­pay­20m­to­end­investor­suits­over­deceptive­pr


(3) https://www.bamsec.com/filing/139047814000016/1?


entity_id=1390478&hl=170312:170583&hl_id=v1ttfebbf


(4) https://dockets.justia.com/docket/oregon/ordce/3:2014cv00435/116313


(5) https://dockets.justia.com/docket/oregon/ordce/3:2015cv01748/123584


(6) https://www.sec.gov/Archives/edgar/data/1390478/000139047814000051/gale­


20140925_pressxrelease.htm


(7) https://www.sec.gov/Archives/edgar/data/1390478/000139047816000167/gale­201612228xk.htm



https://static.seekingalpha.com/uploads/2017/1/40228756_14839399560396_rId17.png

https://www.bamsec.com/filing/95012311033025/1?entity_id=1390478&hl=11183:11394&hl_id=vka6_4srg

http://www.law360.com/articles/734388/galena-to-pay-20m-to-end-investor-suits-over-deceptive-pr

https://www.bamsec.com/filing/139047814000016/1?entity_id=1390478&hl=170312:170583&hl_id=v1ttfebbf

https://dockets.justia.com/docket/oregon/ordce/3:2014cv00435/116313

https://dockets.justia.com/docket/oregon/ordce/3:2015cv01748/123584

https://www.sec.gov/Archives/edgar/data/1390478/000139047814000051/gale-20140925_pressxrelease.htm

https://www.sec.gov/Archives/edgar/data/1390478/000139047816000167/gale-201612228xk.htm
7/7/2019 Abeona Director Implicated In 'Pump And Dump' Lawsuit With SEC Investigation, Price Target Of Zero - Abeona Therapeutics Inc. (NASDAQ:ABEO) …


https://seekingalpha.com/article/4035215-abeona-director-implicated-pump-dump-lawsuit-sec-investigation-price-target-zero 5/12


Source: Justia


According to Lexis Legal News, GALE shareholders that had been burned by the
promotion alleged the following:


Source: Lexis Legal News


Based on the series of events that occurred, it should be no surprise that these lawsuits
resulted in a $20 million settlement, which is unfortunately only a fraction of the $750
million in value lost since the height of the promotion.



https://dockets.justia.com/browse/state-oregon/court-ordce/noscat-13/nos-850

http://www.lexislegalnews.com/articles/4539/galena-biopharma-reaches-20m-settlement-in-securities-lawsuits

http://www.lexislegalnews.com/articles/4539/galena-biopharma-reaches-20m-settlement-in-securities-lawsuits

https://static.seekingalpha.com/uploads/2017/1/40228756_14839399560396_rId25.png

https://static.seekingalpha.com/uploads/2017/1/40228756_14839399560396_rId27.png
7/7/2019 Abeona Director Implicated In 'Pump And Dump' Lawsuit With SEC Investigation, Price Target Of Zero - Abeona Therapeutics Inc. (NASDAQ:ABEO) …


https://seekingalpha.com/article/4035215-abeona-director-implicated-pump-dump-lawsuit-sec-investigation-price-target-zero 6/12


What we find highly alarming are the allegations of what appear to us to be a series of flat
out "inconsistencies" told by Mark Ahn during this whole disaster, as profiled by court
documents. We present some of the most relevant quotes below for you so that you can
come to your own conclusions. For more detail, we recommend that you read the lawsuit
in its entirety. Please carefully comprehend these events and allegations:


Source: [Case 3:15­cv­01748­AC]


Remember that Mark Ahn has been on the board of ABEO while all of these events were
going down. These events were well publicized and thoroughly reported. So why didn't
Rouhandeh, ABEO's chairman, give Mark Ahn the boot from the Abeona board? Who
needs an apparently SEC investigated, alleged insider trader, defendant of a securities
fraud lawsuit and alleged liar on the board of their company? We can't explain how this
would possibly be in the best interest of shareholders, but our best guess is that Mark
Ahn's stock promotion skills have been of critical importance to the ongoing promotion at
ABEO.



https://static.seekingalpha.com/uploads/2017/1/40228756_14839399560396_rId30.png

https://static.seekingalpha.com/uploads/2017/1/40228756_14839399560396_rId31.png
7/7/2019 Abeona Director Implicated In 'Pump And Dump' Lawsuit With SEC Investigation, Price Target Of Zero - Abeona Therapeutics Inc. (NASDAQ:ABEO) …


https://seekingalpha.com/article/4035215-abeona-director-implicated-pump-dump-lawsuit-sec-investigation-price-target-zero 7/12


Round 2: ABEO (aka PTBI & ACCP) Touted by the Same Stock Promoters That
Pumped GALE


Yes, Mission IR, a related company to the disgraced Dream Team Group also was part of
the ongoing ABEO stock promotion. We have seen numerous other Mission IR/Dream
Team Group promotions get wiped out and we believe ABEO will certainly be among them
over time.


Source: Mission IR, Mission IR, Mission IR


Of course, ABEO doesn't provide disclosures for what companies it paid for investor
relations, but we know Mission IR has covered ABEO, and we highly doubt Mission IR
was touting ABEO's prior two tickers for free:


Source: Mission IR


Source: Mission IR


ABEO has spent a truly ridiculous amount of shareholder cash on investor relations
expenses over the years. In 2015 alone, the company spent at least $1.2 million on
investor relations, which dwarfs the amounts that GALE/Ahn had spent on their stock
promotion that preceded GALE's stock getting pummeled. As you remember from our first
report, historically, a large portion of ABEO's investor relations fees and/or services have
actually been paid to Rouhandeh entities ­ in fact, we believe that ABEO appears to us to
exist so that Rouhandeh and other insiders can funnel cash out of the company for their
own benefit, something we covered extensively in our first report on ABEO. Recall,
several prior Rouhandeh stocks essentially went to zero as failed entities and were later
rolled into ABEO. Do ABEO investors think this time will be any different? Do they not
think that the SEC is watching Mark Ahn very closely after the stunt he pulled with GALE?
If Rouhandeh's stock promoter days are really a thing of the past and nothing to worry



https://seekingalpha.com/article/2086173-behind-the-scenes-with-dream-team-cytrx-and-galena

https://seekingalpha.com/article/2112373-behind-the-scenes-with-proactive-inovio-and-unilife

https://web.archive.org/web/20111201092456/http:/www.missionir.com/clients.html

https://web.archive.org/web/20120812055947/http:/www.missionir.com/clients.html

https://web.archive.org/web/20130803065757/http:/www.missionir.com/clients.html

http://missionir.com/blog/small-cap-news/plasmatech-biopharmaceuticals-inc-ptbi-leverages-platforms-to-drive-growth/

http://missionir.com/blog/small-cap-news/access-pharmaceuticals-accp-on-track-to-bring-mugard-to-market-in-china-territories/

https://www.bamsec.com/filing/114420416091600/1?entity_id=318306&hl=127693:127743&hl_id=njguz0dsf

https://static.seekingalpha.com/uploads/2017/1/40228756_14839399560396_rId38.png

https://static.seekingalpha.com/uploads/2017/1/40228756_14839399560396_rId40.png
7/7/2019 Abeona Director Implicated In 'Pump And Dump' Lawsuit With SEC Investigation, Price Target Of Zero - Abeona Therapeutics Inc. (NASDAQ:ABEO) …


https://seekingalpha.com/article/4035215-abeona-director-implicated-pump-dump-lawsuit-sec-investigation-price-target-zero 8/12


about (as the Jefferies analyst Gena Wang wrongly concludes ­ more on Gena below)
then why is he electing some of Wall Street's worst stock promoters to be on the Board of
Directors of ABEO?


Sell­Side Analysts Defending ABEO Have Embarrassing Track Records and Were at
the Epicenter of the China Stock Fraud Bubble


Recently, sell­side analysts have been attempting to defend ABEO, initiating favorable
coverage and assigning outlandish price targets. In December, Cantor Fitzgerald "analyst"
Elemer Piros stated that our report that debunked the ABEO bull case was "factually
incorrect and misleading" and maintained his buy rating and price target of $21. We
laughed when we read the Piros piece because he did not even understand the argument
we made in our first report, though we'll come back to that in our next piece on ABEO's
science. More recently, Jefferies "analyst" Gena Wang came to ABEO's defense, initiating
coverage, rating the shares a buy with an $11 price target.


We think investors have wrongly assigned too much credibility to the words of these two
analysts given the obvious conflicts of interest and the history the two share as part of the
same team at Rodman & Renshaw that regularly touted Chinese life sciences companies
that turned out to be terrible investments, in our view. Below, you can see that both Gena
Wang and Elemer Piros have some of the worst track records as analysts according to
TipRanks:


Source: TipRanks



http://www.streetinsider.com/Analyst+Comments/Abeona+Therapeutics+%28ABEO%29+Defended+at+Cantor+Fitzgerald+Following+Factually+Incorrect+and+Misleading+Article/12333803.html

http://www.streetinsider.com/Analyst+Comments/Jefferies+Starts+Abeona+Therapeutics+%28ABEO%29+at+Buy/12401513.html

https://www.tipranks.com/analysts/gena-wang

https://static.seekingalpha.com/uploads/2017/1/40228756_14839399560396_rId46.png
7/7/2019 Abeona Director Implicated In 'Pump And Dump' Lawsuit With SEC Investigation, Price Target Of Zero - Abeona Therapeutics Inc. (NASDAQ:ABEO) …


https://seekingalpha.com/article/4035215-abeona-director-implicated-pump-dump-lawsuit-sec-investigation-price-target-zero 9/12


Further, we believe investors in ABEO are unaware that both Gena Wang and Elemer
Piros previously worked together at Rodman & Renshaw, a low­quality sell­side shop that
shamelessly promoted Chinese reverse merger stocks before they were eventually
exposed as frauds by professional investors. Many investors know that Rodman &
Renshaw declared bankruptcy some years ago as a direct result of the alleged Chinese
fraud enablement it participated in.


We believe Gena Wang and Elemer Piros served as key players in the Rodman debacle
given that they appear in a research piece that assigned "Market Outperform" ratings to
several Chinese life sciences companies that in aggregate severely underperformed the
market.


Source: Baidu


Below, you can see that in this report, Piros and Wang had rated these companies
"Market Outperform":


Source: Baidu


So what would have happened if you had made an investment in each of these
companies, blindly following the investment recommendations of Wang and Piros and held
them for the next two years? We'll let the charts speak for themselves:



http://www.reuters.com/article/directmarkets-bankruptcy-idUSL4N0AJ7CL20130114

http://abcnews.go.com/Blotter/china-fraud-accusations-wesley-clarks-firm-faces-questions/story?id=18292965

http://wenku.baidu.com/view/6036415c3b3567ec102d8a78.html

https://static.seekingalpha.com/uploads/2017/1/40228756_14839399560396_rId50.png

https://static.seekingalpha.com/uploads/2017/1/40228756_14839399560396_rId52.png
7/7/2019 Abeona Director Implicated In 'Pump And Dump' Lawsuit With SEC Investigation, Price Target Of Zero - Abeona Therapeutics Inc. (NASDAQ:ABEO) …


https://seekingalpha.com/article/4035215-abeona-director-implicated-pump-dump-lawsuit-sec-investigation-price-target-zero 10/12


Source: Capital IQ


Source: Capital IQ


Source: Capital IQ


In our view, there is a clear and relatively consistent pattern emerging from these
recommendations. Not only did these investments lose a substantial amount of value over
the following two years from the date of the report but they also significantly
underperformed the IBB by a wide margin. Look at this chart closely: the amount of
negative alpha created by the Piros and Wang picks is so severe that the chart becomes



https://static.seekingalpha.com/uploads/2017/1/40228756_14839399560396_rId54.png

https://static.seekingalpha.com/uploads/2017/1/40228756_14839399560396_rId55.png

https://static.seekingalpha.com/uploads/2017/1/40228756_14839399560396_rId56.png
7/7/2019 Abeona Director Implicated In 'Pump And Dump' Lawsuit With SEC Investigation, Price Target Of Zero - Abeona Therapeutics Inc. (NASDAQ:ABEO) …


https://seekingalpha.com/article/4035215-abeona-director-implicated-pump-dump-lawsuit-sec-investigation-price-target-zero 11/12


distorted and it's easy to miss that many of these stocks underperformed the index by
nearly 150% in just a few years, not to mention that several of the stocks essentially got
wiped out.


Source: Capital IQ


The key takeaway here is that investors would have fared much better if they would have
simply ignored the advice given by these two and instead invested their money in the
Nasdaq Biotechnology ETF (NASDAQ:IBB). We recommend indexing as a superior
alternative to anyone long ABEO shares.


There is not much else to say about Gena Wang and Elemer Piros, in our view, but we
view their coverage as a red flag. We recommend extreme caution to anyone considering
an investment in ABEO stock.


Conclusion


We are downgrading shares of ABEO to Strong Sell from Sell and reducing our price
target to zero as the people involved here are far worse than even we had thought, which
makes it crystal clear to us what ABEO really is. We believe this stock will end similarly to
prior Ahn and Rouhandeh efforts and find its way to essentially zero over time. Yes, ABEO
has some cash, but like prior efforts, we believe this will mostly evaporate through various
self­enriching wealth transfers from shareholders to insiders.


Stay tuned for the next several installments in our ongoing coverage of ABEO, which will
detail numerous additional problems with the company's science and ongoing
misunderstandings about ABEO's data and trials that persist in the investment community.



https://seekingalpha.com/symbol/IBB

https://static.seekingalpha.com/uploads/2017/1/40228756_14839399560396_rId57.png
7/7/2019 Abeona Director Implicated In 'Pump And Dump' Lawsuit With SEC Investigation, Price Target Of Zero - Abeona Therapeutics Inc. (NASDAQ:ABEO) …


https://seekingalpha.com/article/4035215-abeona-director-implicated-pump-dump-lawsuit-sec-investigation-price-target-zero 12/12


Disclosure: I am/we are short ABEO. I wrote this article myself, and it expresses my own opinions. I am not receiving
compensation for it. I have no business relationship with any company whose stock is mentioned in this article.


Editor's Note: This article covers one or more microcap stocks. Please be aware of the
risks associated with these stocks.


JOIN THE CONVERSATION


Comments (95)


World's Greatest, Contributor
Stockfan1. I am not sure I would go as far as saying patients have been cured! We have data at 6 months in 2
patients.


That said this is a very severe disease in which patients have a very low quality of life and the disease ends in death.
And based on the data available right now it would appear that this drug would appear to slow the progression of the
disease but not much more is known at this time. Despite this, the FDA will want to approve this drug ASAP because
the drug is very clean with no adverse events, it clearly has a positive effect and these patients currently have nothing.


We can spend the next two years participating in intellectual masturbation over which is the worst management team
in the world etc but I think the undebatable fact is that if this drug gets approved the stock is a 10 bagger. I don't think
even mako has disagreed with that.


The clinical trial is conducted outside the company and the management team have no control over either the trial or
the release of the data.


So I would like a bear to tell me why, if the company can replicate the results presented today in a larger patient
population, this drug won't get approved. That is what is important here. Over to you mako. I look forward to an
answer.


17 Feb 2017, 10:43 PM


stockfan1
world's greatest my reference was to spark therapeutics using nationwide children's hospital license(gene
therapy) the same organization licensing to Abeona and their results were fantastic. http://bit.ly/2lvSa3Z


18 Feb 2017, 12:50 PM



https://seekingalpha.com/author/world-s-greatest

https://seekingalpha.com/user/199813

http://bit.ly/2lvSa3Z
